Generate Biomedicines(NASDAQ) GENB

Market Cap$1.79BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)+8%
5 YearN/A
1 YearN/A
1 Month-15%
$13.90
+1.53%
+0.21Today
After hours$13.90+$0.00 (+0.00%)
Generate Biomedicines last closing stock price
MetricPriceDate
Last closeUSD 13.912026-10-05
Generate Biomedicines stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.71%USD 14.912026-09-28
1 month-15.13%USD 16.392026-09-04
3 month-14.24%USD 16.222026-07-07
Since inception+8.22%USD 12.652026-02-27

Generate Biomedicines Financials at a Glance

Market Cap

$1.79BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$32.49

Net Income (TTM)

-$230.02

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.95 (Low)

Price

$13.90

Volume

1,120,020.341

Open

$13.71

Previous Close

$13.91

Daily Range

$13.45 - $14.06

52-Week Range

$11.00 - $22.67

Estimated Earnings Date

N/A

GENB News

Axesome

This Is Nvidia CEO Jensen Huang's Favorite Biotech Stock -- and You've Probably Never Heard of It

James HalleyAug 5, 2026
biotechnology-lab-computer

Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion Market

James BrumleyJun 27, 2026
f5acfa2370b69ef05efd688fbbc9e56e546c0092-1401x1251.png

A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer

Jonathan PoncianoMay 31, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Generate Biomedicines

Generate Biomedicines, Inc. is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company was founded in 2018, and is headquartered in Somerville, MA.

Industry

Biotechnology

Sector

Health Care

Employees

312

CEO

Michael T. Nally, MBA

Website

generatebiomedicines.com

GENB Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$1.79BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

128.35M

Volume

1.12M

Avg. Volume

1.03M

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Generate Biomedicines Performance Analysis

Generate Biomedicines annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20242024-12-31USD 20,459,000N/A
20252025-12-31USD 31,893,00055.9%
Generate Biomedicines annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20242024-12-31USD -1.68N/A
20252025-12-31USD -1.9616.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$6.31

N/A

Gross Profit

$3.09

N/A

Gross Margin

48.94%

N/A

Market Cap

$1.79BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

-$67.26

N/A

EBITDA

-$68.39

N/A

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$197.99

N/A

Total Debt

$62.63

N/A

Accounts Receivable

N/A

N/A

Inventory

$0.00

N/A

Long Term Debt

$49.01

N/A

Short Term Debt

$13.62

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

-61.64%

N/A

Free Cash Flow

-$58.88

N/A

Operating Cash Flow

-$57.94

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,777.74+0.01%
^DJIDJI
$51,304.21+0.00%
^IXICNASDAQ
$27,461.27+0.01%
BTCBitcoin
$85,510.00+0.00%

Questions About GENB

What is the current price of Generate Biomedicines?

Generate Biomedicines is trading at $13.91 per share.

What is the 52-week range for Generate Biomedicines?

Over the past 52 weeks, Generate Biomedicines has traded between $11.00 and $22.67.

How much debt does Generate Biomedicines have?

As of the most recent reporting period, Generate Biomedicines reported total debt of $62.63M.

How much cash does Generate Biomedicines have on hand?

Generate Biomedicines reported $135.36M in cash and cash equivalents in its most recent financial results.

What is Generate Biomedicines’s dividend yield?

Generate Biomedicines does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services